0001493152-24-031437.txt : 20240812 0001493152-24-031437.hdr.sgml : 20240812 20240812215809 ACCESSION NUMBER: 0001493152-24-031437 CONFORMED SUBMISSION TYPE: 3/A PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240124 FILED AS OF DATE: 20240812 DATE AS OF CHANGE: 20240812 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: O'HEERON PETE CENTRAL INDEX KEY: 0001569334 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 3/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-41934 FILM NUMBER: 241198583 MAIL ADDRESS: STREET 1: 17300 EL CAMINEO REAL, SUITE 110 CITY: HOUSTON STATE: TX ZIP: 77058 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: FibroBiologics, Inc. CENTRAL INDEX KEY: 0001958777 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 863329066 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 455 E. MEDICAL CENTER BLVD STREET 2: SUITE 300 CITY: HOUSTON STATE: TX ZIP: 77598 BUSINESS PHONE: 281-671-5150 MAIL ADDRESS: STREET 1: 455 E. MEDICAL CENTER BLVD SUITE 300 STREET 2: SUITE 300 CITY: HOUSTON STATE: TX ZIP: 77598 FORMER COMPANY: FORMER CONFORMED NAME: FibroBiologics Inc. DATE OF NAME CHANGE: 20221216 3/A 1 ownership.xml X0206 3/A 2024-01-24 2024-02-08 0 0001958777 FibroBiologics, Inc. FBLG 0001569334 O'HEERON PETE C/O FIBROBIOLOGICS, INC. 455 E. MEDICAL CENTER BLVD. SUITE 300 HOUSTON TX 77598 1 1 0 0 Chief Executive Officer Series C Preferred Stock 0 Common Stock 2500 D Stock Option (Right to Buy) 2.28 2033-02-16 Common Stock 1853000 D The Series C Preferred Stock is convertible into the issuer's Common Stock on a 1-for-1 basis and has no expiration date. Upon the closing of the issuer's direct listing, the Series C Preferred Stock will convert, without the payment of additional consideration by or to the holder thereof, into the issuer's Common Stock on a 1-for-1 basis upon any transfer of such shares. For as long as they remain outstanding, the Series C Preferred Stock of the issuer held by the Reporting Person are subject to an irrevocable proxy issued by the Reporting Person in favor and for the benefit of the board of directors of the issuer. 1/4 of the options vested on January 1, 2024, with the remainder vesting monthly over 36 months. This amendment is filed to include stock options in Table II that were inadvertently omitted in the original filing and to report the Series C Preferred Stock in Table II instead of Table I. Exhibit 24 - Power of Attorney /s/ Ruben A. Garcia, by Power of Attorney 2024-08-12 EX-24 2 ex24-1.htm

 

Exhibit 24.1

 

Limited Power of Attorney

 

The undersigned, Pete O’Heeron, understands that, from time to time, he is required to prepare, execute and file certain federal and state securities laws filings.

 

The undersigned hereby appoints and authorizes each of Mark Andersen, Chief Financial Officer of FibroBiologics Inc., and Ruben A. Garcia, General Counsel of FibroBiologics Inc., as the undersigned’s true and lawful attorney-in-fact, each with full power of substitution and full power to act alone, to:

 

 1.prepare and sign in the name of and on behalf of the undersigned any and all forms and reports required to be filed pursuant to the Exchange Act of 1933 and the Securities Exchange Act of 1934 and the rules and regulations thereunder, including, but without limitation, Forms 3, 4 and 5 and Schedule 13D/G;
   
 2.perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such forms and filings, and timely file such forms with the United States Securities and Exchange Commission; and
   
 3.take any other action of any type in connection with the foregoing which, in the opinion of the attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Limited Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

 

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever required, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution (including appointing substitutes for themselves, for each other and for any successor to any attorney-in-fact hereunder) or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted.

 

This Limited Power of Attorney shall remain in effect until the undersigned is no longer required to file forms with respect to the securities of FibroBiologics, Inc., unless earlier revoked by the undersigned in a signed and dated writing delivered to the foregoing attorney-in-fact.

 

Executed this 12th day of August, 2024.

 

  /s/ Pete O’Heeron
  Pete O’Heeron